InMed Pharmaceuticals Inc. INM 深 沪
等待开盘 10-10 09:30:00 美东时间
1.36
+0.030
+2.26%
华盛通- 最 高1.44
- 今 开1.35
- 成交量 5.58万股
- 最 低 1.35
- 昨 收 1.33
- 总市值 747.15万
- 52周最高 2.33
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 0.575
- 委 比 82.27%
- 总股本 549.37万
- 历史最高 3210.00
- 量 比 2.24
- 振 幅 6.77%
- 历史最低 0.575
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InMed receives Nasdaq notice over equity requirement
InMed Pharmaceuticals (INM) said on Friday it received a Nasdaq notice after reporting shareholders' equity of $1.08M, below the $2.5M minimum required for continued listing. The company has 45 days t...
09-19 05:47
InMed Pharmaceuticals GAAP EPS of -$3.12
InMed Pharmaceuticals press release (INM): FY GAAP EPS of -$3.12. For the fiscal year ended June 30, 2026, BayMedica, which is presented as discontinued operations, recorded sales of $3.2 million comp...
09-10 04:39
Mentari merger financing reshapes InMed Pharmaceuticals’ future
InMed Pharmaceuticals ( ($INM) ) has issued an update. On July 22, 2026, Mentar...
07-23 04:49
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $...
07-22 19:00
InMed amends merger terms, advances Mentari transition
InMed Pharmaceuticals ( ($INM) ) has provided an update. On July 6, 2026, InMed...
07-11 04:32
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
InMed agrees to merge with Mentari Therapeutics to advance migraine drug candidates backed by $290 million in financing.
05-19 22:05
InMed and Mentari announce all-stock merger deal
Canadian pharmaceutical company InMed Pharmaceuticals (INM) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migraine drug developer Mentari Therapeutics to ...
05-19 20:51
InMed Pharmaceuticals To Merge With Mentari Therapeutics
Upon consummation of the transaction contemplated by the Agreement, the combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol. Mentari's parallel lead
05-19 20:07
